A Study Comparing Standard Treatment versus Accelerated Initiation of Renal Replacement Therapy for Acute Kidney Injury

Overview

About this study

The purpose of this study is to determine if, in critically ill patients with severe acute kidney injury, an earlier start of renal replacement therapy compared to standard treatment will lead to improved survival and recovery of kidney function.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Age ≥ 18 years
  • Admission to an intensive care unit (ICU)
  • Evidence of kidney dysfunction [serum creatinine ≥100 µmol/L (women) and ≥ 130 µmol/L (men)]
  • Evidence of severe acute kidney injury defined by at least 1 of 3 criteria
    • ≥ 2-fold increase in serum creatinine from a known pre-morbid baseline or during the current hospitalization
    • Achievement of a serum creatinine ≥ 354 µmol/L with evidence of a minimum increase of 27 µmol/L from pre-morbid baseline or during the current hospitalization
    • Urine output < 6.0 mL/kg over the preceding 12 hours

Exclusion Criteria

  • Serum potassium > 5.5 mmol/L
  • Serum bicarbonate < 15 mmol/L
  • Presence of a drug overdose that necessitates initiation of renal replacement therapy
  • Lack of commitment to ongoing life support (including RRT)
  • Any RRT within the previous 2 months (either acute or chronic RRT)
  • Kidney transplant within the past 365 days
  • Known pre-hospitalization advanced chronic kidney disease, defined by an estimated glomerular filtration rate < 20 mL/min/1.73 m2
  • Presence or clinical suspicion of renal obstruction, rapidly progressive glomerulonephritis, vasculitis, thrombotic microangiopathy or acute interstitial nephritis
  • Clinician(s) caring for patient believe(s) that immediate RRT is mandated
  • Clinician(s) caring for patient believe(s) that deferral of RRT initiation is mandated
    • at their discretion, clinicians may administer a bolus of intravenous furosemide (ie, "furosemide stress test") and evaluate the subsequent urine output to help guide decision making regarding the likelihood of AKI progression

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Kianoush Banaei Kashani, M.D., M.S.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions